{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:43:01Z","timestamp":1790635381203,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Central precocious puberty (CPP) results from premature activation of hypothalamic-pituitary-gonadal axis, with the consequent increase of gonadotropin-releasing hormone (GnRH); GnRH agonists (GnRHa) represent the gold-standard therapy in children with CPP although their use might be responsible for pituitary GnRH receptors down-regulation, that in turn suppresses luteinizing hormone (LH) and follicle stimulating hormone (FSH) and blocks of gonadal sex hormones release. The most prescribed GnRHa in the clinical practice are leuprolide and triptorelin, whose use is generally safe and well tolerated; however, mild menopausal-like side effects could appear. The aim of the present study was to investigate and compare the efficacy and tolerability profile of leuprolide and triptorelin in CPP patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>110 girls affected by CPP were enrolled in this retrospective study, carried out from 2018 to 2020. The enrolled patients received leuprolide (<jats:italic>n<\/jats:italic>\u2009=\u200948) or triptorelin (<jats:italic>n<\/jats:italic>\u2009=\u200962). Efficacy was investigated by the means of clinical parameters and radiological changes and side effects were also recorded to evaluate the possible relationship between the two GnRHa treatments and side effects appearance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At baseline triptorelin patients had significantly higher LH and LH peak levels than leuprolide patients, whereas no significant difference in other patient characteristics was observed between the two groups. The leuprolide treatment lasted 971 days [790\u20131,171 days] while the duration of triptorelin administration was 792 days [760\u20131,003 days] (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). Overall 46 (41.8%) of the studied patients reported mild menopausal-like symptoms: among these 27 were treated with triptorelin and 19 with leuprolide (<jats:italic>p<\/jats:italic>\u2009=\u20090.558). Patients treated with triptorelin, or leuprolide showed headache (27.4% vs. 16.7%), mood swings (12.9% vs. 16.7%), increased appetite (12.9% vs. 18.8%) and nausea (1.6% vs. 10.4%) respectively. Moreover, the onset of side effects appearance related to GnRHa therapy significantly reduces with the increase of the initial bone age (<jats:italic>p<\/jats:italic>\u2009=\u20090.038).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Leuprolide and triptorelin treatment appear to be effective and safe without significant difference between the two drugs in term of efficacy and tolerability, making both good options for treating CPP.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1170025","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T05:30:14Z","timestamp":1684301414000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Leuprolide and triptorelin treatment in children with idiopathic central precocious puberty: an efficacy\/tolerability comparison study"],"prefix":"10.3389","volume":"11","author":[{"given":"M.","family":"Valenzise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Nasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Scarfone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Rottura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cafarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Visalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Di Prima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Nasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Squadrito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wasniewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Irrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Arcoraci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Squadrito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2213-8587(15)00380-0","article-title":"Causes, diagnosis, and treatment of central precocious puberty","volume":"4","author":"Latronico","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000087753","article-title":"Early onset of puberty: tracking genetic and environmental factors","volume":"64","author":"Parent","year":"2005","journal-title":"Horm Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1210\/er.2002-0019","article-title":"The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration","volume":"24","author":"Parent","year":"2003","journal-title":"Endocr Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.l6597","article-title":"Precocious puberty","volume":"368","author":"Bradley","year":"2020","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000087760","article-title":"Precocious puberty: growth and genetics","volume":"64","author":"Phillip","year":"2005","journal-title":"Horm Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1542\/peds.2005-0012","article-title":"Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries","volume":"116","author":"Teilmann","year":"2005","journal-title":"Pediatrics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1542\/peds.2012-3773","article-title":"Onset of breast development in a longitudinal cohort","volume":"132","author":"Biro","year":"2013","journal-title":"Pediatrics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000366282","article-title":"New causes of central precocious puberty: the role of genetic factors","volume":"100","author":"Bulcao Macedo","year":"2014","journal-title":"Neuroendocrinology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1542\/peds.2008-1783","article-title":"Consensus statement on the use of gonadotropin-releasing hormone analogs in children","volume":"123","author":"Carel","year":"2009","journal-title":"Pediatrics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1018","DOI":"10.1016\/S2214-109X(20)30285-0","article-title":"Ethnic and regional variations in hospital mortality from COVID-19 in Brazil: a cross-sectional observational study","volume":"8","author":"Baqui","year":"2020","journal-title":"Lancet Glob Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s00787-020-01583-8","article-title":"Finding ordinary magic in extraordinary times: child and adolescent resilience during the COVID-19 pandemic","volume":"30","author":"Dvorsky","year":"2021","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.chiabu.2020.104663","article-title":"Psycho-social impact of COVID-19 pandemic on children in India: the reality","volume":"108","author":"Dave","year":"2020","journal-title":"Child Abuse Negl"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/oby.22861","article-title":"Effects of COVID-19 lockdown on lifestyle behaviors in children with obesity living in verona, Italy: a longitudinal study","volume":"28","author":"Pietrobelli","year":"2020","journal-title":"Obesity"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13052-020-00931-3","article-title":"Increased incidence of precocious and accelerated puberty in females during and after the Italian lockdown for the coronavirus 2019 (COVID-19) pandemic","volume":"46","author":"Stagi","year":"2020","journal-title":"Ital J Pediatr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.6065\/apem.2015.20.3.130","article-title":"The effect of early menarche on the sexual behaviors of Korean female adolescents","volume":"20","author":"Cheong","year":"2015","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1745-7262.2008.00409.x","article-title":"Treatment of central precocious puberty by GnRH analogs: long-term outcome in men","volume":"10","author":"Bertelloni","year":"2008","journal-title":"Asian J Androl"},{"key":"B17","author":"Cisternino","year":""},{"key":"B18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1530\/EC-20-0651","article-title":"Clinical data and basal gonadotropins in the diagnosis of central precocious puberty in girls","volume":"10","author":"Dur\u00e1-Trav\u00e9","year":"2021","journal-title":"Endocr Connect"},{"key":"B19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/adc.44.235.291","article-title":"Variations in pattern of pubertal changes in girls","volume":"44","author":"Marshall","year":"1969","journal-title":"Arch Dis Child"},{"key":"B20","author":"Gilsanz","year":""},{"key":"B21","author":"Sun","year":""},{"key":"B22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10654-019-00494-6","article-title":"Principles of confounder selection","volume":"34","author":"VanderWeele","year":"2019","journal-title":"Eur J Epidemiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e2015665","DOI":"10.1001\/jamanetworkopen.2020.15665","article-title":"Trends in the incidence of central precocious puberty and normal variant puberty among children in Denmark, 1998 to 2017","volume":"3","author":"Br\u00e4uner","year":"2020","journal-title":"JAMA Netw Open"},{"key":"B24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.20945\/2359-3997000000241","article-title":"Challenges in monitoring GnRH analog treatment in central precocious puberty","volume":"64","author":"Latronico","year":"2020","journal-title":"Arch Endocrinol Metab"},{"key":"B25","author":"L\u00e9ger","year":""},{"key":"B26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/MED.0b013e328320a650","article-title":"Treatment of central precocious puberty. Current opinion in endocrinology","volume":"16","author":"Kaplowitz","year":"2009","journal-title":"Diabetes Obes"},{"key":"B27","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1515\/jpem-2017-0523","article-title":"Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate","volume":"31","author":"Klein","year":"2018","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.23750\/abm.v90i3.8736","article-title":"Long-term effects and significant adverse drug reactions (ADRs) associated with the use of gonadotropin-releasing hormone analogs (GnRHa) for central precocious puberty: a brief review of literature","volume":"90","author":"de Sanctis","year":"2019","journal-title":"Acta Biomed"},{"key":"B29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4274\/jcrpe.2017.S004","article-title":"A critical appraisal of the effect of gonadotropin-releasing hormon analog treatment on adult height of girls with central precocious puberty","volume":"9","author":"Bereket","year":"2017","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"B30","author":"Carel","year":""},{"key":"B31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1530\/EJE-08-0814","article-title":"The use of GnRH agonists in precocious puberty","volume":"159","author":"Mul","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B32","author":"Mul","year":""},{"key":"B33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/17446651.2019.1575726","article-title":"Update on central precocious puberty: from etiologies to outcomes","volume":"14","author":"Cantas-Orsdemir","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40272-015-0130-8","article-title":"Central precocious puberty: update on diagnosis and treatment","volume":"17","author":"Chen","year":"2015","journal-title":"Pediatr Drugs"},{"key":"B35","first-page":"795","article-title":"Side effects of GnRH analogue treatment in childhood","volume-title":"J Pediatr Endocrinol Metab","author":"Tonini","year":"2000"},{"key":"B36","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1515\/jpem-2020-0470","article-title":"Short-term effects of gonadotropin-releasing hormone analogue treatment on leptin, ghrelin and peptide YY in girls with central precocious puberty","volume":"34","author":"Wijarn","year":"2021","journal-title":"J Pediatr Endocrinol Metab"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1170025\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T05:30:20Z","timestamp":1684301420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1170025\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":36,"alternative-id":["10.3389\/fped.2023.1170025"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1170025","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"article-number":"1170025"}}